Complete Genomics to Bundle Ingenuity Analysis and Interpretation Software With Whole Genome Sequencing
Integrated workflow enables integrated sample-to-insight solution.
Mountain View and Redwood City, CA – July 24, 2012 – Complete Genomics Inc. (NASDAQ: GNOM) and Ingenuity® Systems Inc. today announced that Complete Genomics will bundle the Ingenuity Variant Analysis application with its research whole genome sequencing services. This bundled solution will enable research customers to rapidly analyze and interpret biologically relevant genetic variations and provide researchers with a unique, fully integrated, sample-to-insight workflow. Financial details of this agreement were not disclosed.
Complete Genomics’ outsourced service offers the most accurate whole human genome sequencing and analysis available today. Researchers using Complete’s services will now have an end-to-end solution for the analysis and interpretation of their DNA sequencing data, allowing them to rapidly identify and prioritize variants in hours, a process that otherwise can take weeks to months. Variant Analysis leverages the Ingenuity Knowledge Base and advanced analytics to speed the identification and prioritization of variants through the application of relevant biological information and additional variant-specific content. All orders for new research genomes placed starting today will include access to Ingenuity Variant Analysis for six months.
“The downstream analysis of Next Generation Sequencing data continues to be a critical rate-limiting factor in our ability to gain insights from sequencing data,” said Dr. Leonard Sender, M.D., clinical professor of medicine, University of California, Irvine. “Ingenuity and Complete have addressed that challenge by providing an integrated solution that will dramatically accelerate and simplify our research and help us identify disease-causing variants in a fraction of the time.”
“The combination of Ingenuity and Complete Genomics yields a powerful workflow for the analysis of whole genome data,” said Gustavo Glusman, senior research scientist at the Institute for Systems Biology. “It makes it very easy and fast to go all the way from DNA samples to insights about disease-causing variants. The expert-curated biological content and flexible filtering method make it very convenient for exploring genomes. Using the Ingenuity Variant Analysis system, we quickly identified novel candidate variants for a rare hereditary disease that we studied using Complete Genomics’ whole genome sequence data.”
As part of this agreement, Complete’s customers using Ingenuity Variant Analysis will receive access to the Wellderly whole genome sequence data set being developed in collaboration with Scripps Health. This data set, which will eventually include 1,000 healthy volunteers’ genomes, will be an ideal control for genetic studies of late-onset diseases such as various cancers, heart disease, Alzheimer’s disease and Parkinson’s disease. Access to this control data set will be as easy as selecting a single check box to remove the common variants found in the Wellderly data set.
“With Ingenuity Variant Analysis as an integrated component of our sequencing service, what was the laborious task of identifying, annotating and prioritizing variants can be done within hours,” said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics.
About Ingenuity® Systems
Ingenuity Systems is a leading provider of information and analysis solutions for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. For more information visit: www.ingenuity.com.
About Complete Genomics
Through its pioneering sequencing-as-a-service model, Complete Genomics provides the most accurate whole human genomes available today. The ease of use and power of Complete’s advanced informatics and analysis systems provide genomic information needed to better understand the prevention, diagnosis and treatment of diseases. Additional information can be found at http://www.completegenomics.com.
Caution Regarding Forward-Looking Statement
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, including statements regarding the expected benefits of combining the Ingenuity Variant Analysis application with Complete’s sequencing services. These forward-looking statements are based on management’s current expectations, are not guarantees of future performance, and involve certain risks and uncertainties that could cause actual results to differ materially from management’s current expectations and these forward-looking statements. These risk and uncertainties include, but are not limited to, whether the combined services offering proves to be a useful tool to researchers and other risks detailed in Complete’s most recent Annual Report on Form 10-K, filed with the SEC on March 9, 2012, and Quarterly Report on Form 10-Q, filed with the SEC on May 9, 2012. We disclaim any obligation to update information contained in our forward-looking statements, whether as a result of new information, future events or otherwise.
SVP, Marketing and Products
Complete Genomics Contact:
Waggener Edstrom Worldwide Healthcare